Numab
Matthias Fehr was appointed to the Numab Board of Directors in June 2021. He currently holds the position of Head of Private Equity at HBM Partners. Mr. Fehr has more than twenty years of experience in private and public equity investment management and research. He is a former senior sell-side analyst at Lombard Odier for the biotech and medical technology industries.
Matthias Fehr is a former scientist at the Swiss Federal Institute of Technology and holds an MSc and Ph.D. in chemistry from ETH Zurich. He is also a Chartered Financial Analyst since 2002.
Mr. Fehr currently also serves on the board of Swixx Biopharma, Sphingotec, and Farmalatam.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Numab
Numab Therapeutics is an oncology-focused biopharmaceutical company based in the Zurich-area, Switzerland. At Numab, they are writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies.